OTL 201
Alternative Names: OTL-201Latest Information Update: 02 Feb 2024
At a glance
- Originator Central Manchester University Hospitals NHS Foundation Trust; University of Manchester
- Developer Orchard Therapeutics; University of Manchester
- Class Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements; N-sulfoglucosamine sulfohydrolase expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Mucopolysaccharidosis III
Most Recent Events
- 24 Jan 2024 Orchard Therapeutics has been acquired by Kyowa Kirin
- 03 Aug 2023 Updated efficacy data from a phase I/II trial in mucopolysaccharidosis type IIIA (MPS-IIIA) released by Orchard Therapeutics
- 12 Dec 2022 Efficacy and adverse events data from a phase-I/II trial in Mucopolysaccharidosis-III released by Orchard Therapeutics